Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-randomized, Balanced, Crossover Bioequivalence Study to Compare One MR Tablet of 60 mg Gliclazide and Two MR Tablets of 30 mg Gliclazide in Healthy Subjects

NCT01195532 is registered in ClinicalTrials.gov with Taipei Medical University WanFang Hospital as lead sponsor.

NCT NCT01195532
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01195532 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-randomized, Balanced, Crossover Bioequivalence Study to Compare One MR Tablet of 60 mg Gliclazide and Two MR Tablets of 30 mg Gliclazide in Healthy Subjects
Lead sponsor
Taipei Medical University WanFang Hospital
Phase
Observational
Overall status
Unknown status
Start date
January 31, 2010
Completion date
January 31, 2011
Enrollment
40 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

diabetes, hyperglycemia